T. Wielgos

Case study: contamination of heparin with oversulfated chondroitin sulfate.

E. Moore, Shawn F. Bairstow, E. Chess, 2012, Handbook of experimental pharmacology.

Structure Elucidation and Biological Activity of the Oversulfated Chondroitin Sulfate Contaminant in Baxter Heparin

Shawn F. Bairstow, E. Chess, Jon N. Cammack, 2010, Journal of clinical pharmacology.

A Clay Modified Electrode for Ion-Exchange Voltammetry

A. Fitch, T. Wielgos, 1990 .

Determination of impurities in heparin by capillary electrophoresis using high molarity phosphate buffers.

R. Weinberger, K. Havel, T. Wielgos, 2009, Journal of pharmaceutical and biomedical analysis.

Quantitation of oxidized and reduced glutathione in plasma by micellar electrokinetic capillary electrophoresis.

K. Havel, T. Wielgos, K. Pritts, 1999, Journal of chromatography. A.

Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat.

Joseph Wong, Pavlos Papadopoulos, Pavlos Papadopoulos, 2007, International journal of pharmaceutics.

Multi-gram synthesis of a porphyrazine platform for cellular translocation, conjugation to Doxorubicin, and cellular uptake

A. Barrett, B. Hoffman, T. Hai, 2012 .